Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis
- PMID: 25082819
- PMCID: PMC7965919
- DOI: 10.3174/ajnr.A4066
Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis
Abstract
Background and purpose: Intraprocedural thrombus formation during endovascular treatment of intracranial aneurysms is often treated with glycoprotein IIb/IIIa inhibitors and, in some instances, fibrinolytic therapy. We performed a meta-analysis evaluating the safety and efficacy of GP IIb/IIIa inhibitors compared with fibrinolysis. We also evaluated the safety and efficacy of abciximab, an irreversible inhibitor, compared with tirofiban and eptifibatide, reversible inhibitors of platelet function.
Materials and methods: We performed a comprehensive literature search for studies on rescue therapy for intraprocedural thromboembolic complications with glycoprotein IIb/IIIa inhibitors or fibrinolysis during endovascular treatment of intracranial aneurysms. We studied rates of periprocedural stroke/hemorrhage, procedure-related morbidity and mortality, immediate arterial recanalization, and long-term good clinical outcome. Event rates were pooled across studies by using random-effects meta-analysis.
Results: Twenty-three studies with 516 patients were included. Patients receiving GP IIb/IIIa inhibitors had significantly lower perioperative morbidity from stroke/hemorrhage compared with those treated with fibrinolytics (11.0%; 95% CI, 7.0%-16.0% versus 29.0%; 95% CI, 13.0%-55.0%; P = .04) and were significantly less likely to have long-term morbidity (16.0%; 95% CI, 11.0%-21.0% versus 35.0%; 95% CI, 17.0%-58.0%; P = .04). There was a trend toward higher recanalization rates among patients treated with glycoprotein IIb/IIIa inhibitors compared with those treated with fibrinolytics (72.0%; 95% CI, 64.0%-78.0% versus 50.0%; 95% CI, 28.0%-73.0%; P = .08). Patients receiving tirofiban or eptifibatide had significantly higher recanalization rates compared with those treated with abciximab (83.0%; 95% CI, 68.0%-91.0% versus 66.0%; 95% CI, 58.0%-74.0%; P = .05). No difference in recanalization was seen in patients receiving intra-arterial (77.0%; 95% CI, 66.0%-85.0%) or intravenous GP IIb/IIIa inhibitors (70.0%; 95% CI, 57.0%-80.0%, P = .36).
Conclusions: Rescue therapy with thrombolytic agents resulted in significantly more morbidity than rescue therapy with glycoprotein IIb/IIIa inhibitors. Tirofiban/eptifibatide resulted in significantly higher recanalization rates compared with abciximab.
© 2015 by American Journal of Neuroradiology.
Similar articles
-
Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis.Neuroradiol J. 2024 Apr;37(2):152-163. doi: 10.1177/19714009231166090. Epub 2023 Mar 24. Neuroradiol J. 2024. PMID: 36961079 Review.
-
Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms.Neurosurgery. 2018 Mar 1;82(3):268-277. doi: 10.1093/neuros/nyx170. Neurosurgery. 2018. PMID: 28472526 Review.
-
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.Cochrane Database Syst Rev. 2014 Mar 8;(3):CD005208. doi: 10.1002/14651858.CD005208.pub3. Cochrane Database Syst Rev. 2014. PMID: 24609741 Review.
-
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.J Thromb Thrombolysis. 2001 May;11(3):203-9. doi: 10.1023/a:1011904718960. J Thromb Thrombolysis. 2001. PMID: 11577258
-
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.Am Heart J. 1999 Oct;138(4 Pt 2):307-16. doi: 10.1053/hj.1999.v138.a100460. Am Heart J. 1999. PMID: 10502236 Review.
Cited by
-
Risk factors for intraoperative in-stent thrombosis during stent-assisted coiling of paraclinoid aneurysms.Front Neurol. 2024 Jan 12;14:1333075. doi: 10.3389/fneur.2023.1333075. eCollection 2023. Front Neurol. 2024. PMID: 38283676 Free PMC article.
-
Local thrombolytics via balloon-assisted intra-arterial infusion as rescue therapy for thromboembolism during endovascular coil embolisation.BMJ Case Rep. 2023 Oct 24;16(10):e256134. doi: 10.1136/bcr-2023-256134. BMJ Case Rep. 2023. PMID: 37879706 Free PMC article.
-
An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives.High Blood Press Cardiovasc Prev. 2023 Mar;30(2):93-107. doi: 10.1007/s40292-023-00562-9. Epub 2023 Jan 13. High Blood Press Cardiovasc Prev. 2023. PMID: 36637623 Review.
-
Effect of antiplatelet treatment on aneurysmal subarachnoid hemorrhage patients after endovascular treatment: a systematic review with meta-analysis.Neurosurg Rev. 2022 Dec;45(6):3523-3536. doi: 10.1007/s10143-022-01877-2. Epub 2022 Sep 30. Neurosurg Rev. 2022. PMID: 36178562 Review.
-
Postprocedural Thrombosis following Endovascular Treatment of Intracranial Aneurysm with Flow Diverters or Coiling: A Histologic Study.AJNR Am J Neuroradiol. 2022 Feb;43(2):258-264. doi: 10.3174/ajnr.A7369. Epub 2021 Dec 16. AJNR Am J Neuroradiol. 2022. PMID: 34916206 Free PMC article.
References
-
- Ries T, Siemonsen S, Grzyska U, et al. . Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. Stroke 2009;40:1750–57 - PubMed
-
- Jeong HW, Jin SC. Intra-arterial infusion of a glycoprotein IIb/IIIa antagonist for the treatment of thromboembolism during coil embolization of intracranial aneurysm: a comparison of abciximab and tirofiban. AJNR Am J Neuroradiol 2013;34:1621–25 - PubMed
-
- Jones RG, Davagnanam I, Colley S, et al. . Abciximab for treatment of thromboembolic complications during endovascular coiling of intracranial aneurysms. AJNR Am J Neuroradiol 2008;29:1925–29 - PubMed
-
- Brinjikji W, McDonald JS, Kallmes DF, et al. . Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms. Stroke 2013;44:1343–47 - PubMed
-
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical